On July 13, 2018 Taiho Pharmaceutical Co., Ltd. reported that it has exercised the option to adenosine receptor antagonists from Arcus Biosciences, a U.S.-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies (Press release, Taiho, JUL 13, 2018, View Source [SID1234527686]). With the exercise of the option, Taiho has the exclusive right to develop and commercialize AB928 and backup compounds in Japan and certain other territories in Asia (excluding China). The option exercise is based on the Option and License Agreement contracted in September 2017.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AB928 is an orally bioavailable small molecule compound which inhibits the adenosine 2a and 2b receptors. The activation of these receptors by adenosine on tumor infiltrating immune cells is thought to be one of the key mechanisms of immuno-suppression in the tumor microenvironment. AB928 may have the ability to reverse this situation by blocking these receptors. While adenosine receptor antagonists are being developed for several diseases other than cancer, AB928 was designed specifically for the oncology setting. Adenosine receptor antagonists have been an area of significant interest for many researchers, bio-tech and large pharmaceutical companies in the last decade.
In a Phase-I clinical trial in healthy volunteers conducted by Arcus, the safety, tolerability, pharmacokinetic and pharmacodynamic profile of AB928 was evaluated. Arcus has initiated several Phase-I/Ib studies to investigate the safety and clinical activity of AB928 in combination with chemotherapy or an anti-PD1 antibody in multiple types of cancer. Taiho and Arcus will work collaboratively to effectively investigate the optimal therapeutic approach and bring AB928 to cancer patients as quickly as possible.
Through this collaboration, Taiho continues its mission to deliver innovative drugs to patients and medical professionals.